Lachnospiraceae

Your colon lining does not run mainly on intact food. Much of its fuel comes from butyrate. Bacteria make butyrate when they ferment fiber you cannot digest yourself. Lachnospiraceae does much of that work, and in population studies it can account for about a tenth of the gut community, sometimes more.

This test tells you how much of that family is present in your stool. It is a research-grade measurement, not a diagnosis. There are no validated healthy reference ranges, and a single number should not drive a medical decision on its own. What it can do is give you a baseline for a system that standard blood work never touches.

What the Test Actually Measures

Lachnospiraceae is a taxonomic family of bacteria that mostly live in the colon and do not grow well in oxygen. The assay extracts bacterial DNA from a stool sample and uses PCR to estimate how much of that DNA belongs to this family. PCR copies selected DNA sequences until they can be counted.

The family is large. It contains Blautia, Roseburia, Coprococcus, Dorea, Lachnospira, and Anaerostipes, among others. These genera do not all do the same thing. That single fact explains most of the confusion around this test, and it comes back repeatedly below.

Many members ferment fiber and resistant starch into short-chain fatty acids: butyrate, acetate, and propionate. These are small compounds bacteria make from carbohydrates. Butyrate is a major fuel for the cells lining your colon. Through these products, members of the family may also help steer your immune system toward tolerance rather than inflammation. Some can also use mucus as fuel, which may be useful in balance and harmful if the mucus layer is being overused.

Inflammatory Bowel Disease

The strongest and most consistent human finding is that this family often drops when the colon is inflamed. Depletion shows up in active ulcerative colitis, in Crohn's disease, and in chronic pouchitis, where genera including Dorea are markedly reduced. In a study of 180 people with ulcerative colitis in China, both stool and gut-wall abundance fell progressively as inflammation worsened.

One 2026 study of 119 people proposed a mechanism beyond butyrate. Lachnospiraceae members appear to handle the final steps of bilirubin breakdown in the lower gut, turning upstream compounds into the brown pigments that normally end up in stool. When the family thins out, that pathway stalls. The authors linked the disruption to oxidative stress and inflammation in inflammatory bowel disease. Oxidative stress means reactive molecules are outpacing the body's defenses against them.

If you already have a diagnosed inflammatory bowel condition, a low result here fits what is known about the disease, but it does not tell you whether you are in a flare. Fecal calprotectin is the established marker for that. It comes from white blood cells in the gut wall.

Colorectal Cancer and Adenomas

This is where the family has been pushed hardest toward real clinical use, and the results show what a single bacterial marker can and cannot do. The best-studied target is not total Lachnospiraceae. It is a specific gene marker called m3 from Lachnoclostridium, a genus within this family. That marker rises steadily from healthy colon to adenoma to invasive cancer.

On its own it is a mediocre test. In a multi-center study of 2,563 people, m3 separated colorectal cancer from controls with an area under the curve of 0.701, and advanced adenomas at 0.604. An area under the curve of 0.5 is a coin flip and 1.0 is perfect, so 0.60 for precancerous lesions is weak. A separate prospective trial put it at 0.63 for cancer and 0.59 for advanced adenomas.

Combined, it becomes more useful. When m3 was paired with three other microbial markers and a quantitative fecal immunochemical test, the standard stool test for hidden blood, the panel reached an area under the curve of 0.96 for colorectal cancer. It caught about 88 out of 100 cases and correctly cleared about 90 out of 100 people without cancer. For advanced adenomas the combined panel caught about 64 out of 100, rising to about 72 out of 100 for the higher-risk ones. That panel is still a research tool awaiting independent validation, not something you can order as a screening test.

There is a real cost to this approach. A separate modeling study combined the stool blood test with a broader stool microbiome pattern that included several Lachnospiraceae-related sequence groups. Adenoma detection rose from about 16 out of 100 to about 46 out of 100, but specificity dropped, and the authors projected that applying the model to everyone of screening age would add a large number of false positives. Each of those is a person sent for an unnecessary colonoscopy.

The rule is simple: none of this replaces colonoscopy, and none of it is a reason to skip one. If you are due for colorectal screening, get screened by an established method. Treat a microbial marker as supplementary information, not as a substitute.

Liver Disease and Metabolic Markers

Lower abundance often tracks with severity in cirrhosis, alcohol-associated liver disease, and fatty liver disease, and with worse prognosis in liver disease cohorts. In one study of older adults, members including Anaerostipes correlated inversely with the liver enzymes ALT, AST, and GGT. Those blood markers rise when liver cells are stressed or damaged.

In children with fatty liver disease, reduced Lachnospira species tracked with higher insulin resistance. But the direction is not uniform. In school-aged children, fecal abundance of the family measured by PCR correlated positively with blood triglycerides, and gut composition is likewise shifted in older adults with high blood lipids. Genetic analysis of Lachnoclostridium, one genus in this family, points a third way: higher abundance there was linked to lower odds of fatty liver disease. That is the point. The family-level number mixes organisms with different jobs.

Why Higher Is Not Automatically Better

The popular framing treats this family as pure probiotic: more is good, less is bad. The evidence does not support that. You are measuring a family that contains hundreds of strains with different jobs, so a single family-level number averages together organisms that push in opposite directions.

Concrete examples. Higher fecal abundance correlates with worse gum disease, tracking with bleeding scores and pocket depth, and falls after periodontal treatment. Enrichment shows up in gestational diabetes, in severe obstructive sleep apnea, and in obesity, where higher family abundance has correlated with body fat in one adult cohort. In people with a head and neck cancer treated with immunotherapy, higher baseline Lachnoclostridium predicted faster cancer progression. In major depression, a systematic review found the direction of the association split roughly evenly across studies.

Human genetic studies sharpen the point. Mendelian randomization uses inherited genetic variants as a natural experiment. It can strengthen causal inference because genes are assigned before disease starts, though it still depends on assumptions. Applied here, it splits the family apart. One subgroup, Lachnospiraceae FCS020, associates with roughly 40% lower odds of colorectal cancer. Lachnospiraceae UCG-008 associates with about 16% higher odds of periodontitis. In chronic kidney disease the family overall looks protective while the UCG010 subgroup looks harmful. At the family level, no causal link to ankylosing spondylitis was found at all.

Read your result as a coarse ecological signal, not as a score. A low number in someone with gut symptoms means something different from a low number in a healthy person eating plenty of fiber.

Why a Single Sample Can Fool You

This is the main practical limitation, and it comes first for a reason. Quantitative profiling found that 78% of gut genera swing more within one person from day to day than they do between different people, with some shifting up to 100-fold over six weeks. Across three consecutive days, individual genera varied by an average of 57%, and major butyrate producers varied by more than 30%.

The wider picture is steadier. Community structure, diversity, and the number of genera present stay relatively stable day to day and do not drift much with normal changes in stool consistency. It is the individual taxa that jump around.

Laboratory technique adds a second layer. Across 2,722 samples, the DNA extraction method had the largest single technical effect on measured composition, driven by how efficiently different kits break open bacteria with thick cell walls, including many members of this family. In a head-to-head comparison, one common kit recovered about 37% less Lachnospiraceae than another from the same samples. Different PCR primers pick up different subgroups of the family, which is why results from different testing methods frequently disagree.

Two consequences follow. Never compare a result from one lab to a result from another. And do not read a modest change between two samples as a real shift; it may just be Tuesday.

One Confounder Worth Knowing

Where the sample comes from matters. Lachnospiraceae dominates the microbial community attached to the sigmoid colon wall, while stool from the same people shows relatively more Ruminococcaceae. Stool is a convenient proxy for the gut, not a direct readout of what is happening at the gut lining where inflammation occurs.

Reading a Trend

Given the variability, a single reading is close to uninterpretable on its own. A repeated pattern is more useful, especially when samples are collected under similar conditions and run by the same lab.

Expect meaningful movement only from sustained changes. Controlled feeding trials have shifted this family within days, but in your own repeat samples the day-to-day noise swamps anything smaller than a change you have held for weeks. Short antibiotic depletion can rebound quickly in some studies, but that does not mean every taxon has fully returned to your personal baseline.

What to Do With an Unexpected Result

Start by asking what else is true. A low number alongside loose stools, blood, urgency, or unexplained weight loss is a reason to order fecal calprotectin and see a gastroenterologist. Those symptoms warrant investigation regardless of what any microbial marker says, and calprotectin is the marker that actually tracks gut inflammation.

A low number with no symptoms in someone who recently finished antibiotics is expected, and the right move is to retest in a couple of months rather than to act. A low number in someone eating very little fiber points at diet first.

If your result is low and your liver enzymes or triglycerides are also drifting up, that combination is worth taking more seriously than either finding alone. A liver panel and a lipid panel cost little and carry far more established interpretive weight than this marker does. If you are at the age for colorectal screening, book the colonoscopy. No stool bacterial marker changes that recommendation in either direction.